Sepsis Diagnostics Market By Product (Instruments, Blood Culture Media, Assay Kits & Reagents and Software) By Technology (Microbiology, Molecular Diagnostics, Immunoassays, Biomarkers and Others) By Pathogen (Bacterial, Fungal and Others) By End Users (Pathology Laboratories, Hospitals, Research Laboratories & Academic Institutes and Others), and By Region - Trends, Analysis, and Forecast till 2029

Report Code: PMI458921 | Publish Date: May 2024 | No. of Pages: 180

Global Sepsis Diagnostics Market Companies

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Cepheid Inc.
  • Luminex Corporation
  • T2 Biosystems, Inc.
  • Thermo Fisher Scientific, Inc.
  • bioMérieux S.A.
  • Bruker Corporation
  • Roche Diagnostics Limited.

Recent News:

  • In February 2023, Immunexpress commercialized the SeptiCyte rapid test in the United States, which can rapidly diagnose sepsis in patients within an hour. Point-of-care testing can help clinicians identify patients at an earlier stage, leading to timely intervention and better outcomes.
  •  In January 2023, Cytovale announced the launch of its new sepsis diagnostic test IntelliSep. The new test is being deployed to treat patients with sepsis in the emergency department.
  • In January 2023, PERSOWN Inc. launched SMASH-H, a real-time sepsis monitoring system in an effort to address the growing burden of sepsis.